NASDAQ:EYPT Eyepoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $0.23 -0.03 (-11.81%) Closing price 03:59 PM EasternExtended Trading$0.24 +0.00 (+2.15%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Eyepoint Pharmaceuticals Stock (NASDAQ:EYPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get EYPT alerts:Sign Up Key Stats Today's Range$0.23▼$0.2750-Day Range$0.23▼$4.2552-Week Range$0.23▼$19.11Volume4.93 million shsAverage Volume10.15 million shsMarket Capitalization$20.09 millionP/E RatioN/ADividend YieldN/APrice Target$21.85Consensus RatingHold Company Overview EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023. Founded as pSivida, the company adopted the EyePoint Pharmaceuticals name in 2018. It is based in Watertown, Massachusetts, and its development and commercial activities are centered on ophthalmology.AI Generated. May Contain Errors. Read More Eyepoint Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreEYPT MarketRank™: 3.229881900575 of 5 starsEyepoint Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 268th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingEyepoint Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 9 hold ratings, and 2 sell ratings.Upside PotentialEyepoint Pharmaceuticals has a consensus price target of $21.85, representing about 9,277.7% upside from its current price of $0.23.Amount of Analyst CoverageEyepoint Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eyepoint Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eyepoint Pharmaceuticals are expected to grow in the coming year, from ($3.57) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyepoint Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyepoint Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyepoint Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.47% of the float of Eyepoint Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 0.37, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyepoint Pharmaceuticals has recently decreased by 48.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyepoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyepoint Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.13 News SentimentEyepoint Pharmaceuticals has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Eyepoint Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Eyepoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eyepoint Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders5.13% of the stock of Eyepoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eyepoint Pharmaceuticals' insider trading history. Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EYPT Stock News HeadlinesEyePoint, Inc. (NASDAQ: EYPT) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in EyePoint, Inc. Securities Lawsuit – Contact Portnoy Law Firm4 hours ago | globenewswire.comROSEN, A RANKED AND LEADING LAW FIRM, Encourages EyePoint, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Lawsuit - EYPTNovember 19 at 3:32 PM | globenewswire.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 20 at 1:00 AM | Behind the Markets (Ad)EYPT Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against EyePoint, Inc.November 19 at 11:36 AM | prnewswire.comHC Wainwright Issues Pessimistic Estimate for EYPT EarningsNovember 19 at 1:42 AM | americanbankingnews.comEYPT Investors Have Opportunity to Lead EyePoint, Inc. Securities Fraud LawsuitNovember 18 at 1:46 PM | prnewswire.comRosen Law Firm Urges EyePoint, Inc. (NASDAQ: EYPT) Stockholders to Contact the Firm for Information About Their RightsNovember 18 at 11:41 AM | businesswire.comEYPT INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of EyePoint, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the FirmNovember 18 at 10:54 AM | globenewswire.comSee More Headlines EYPT Stock Analysis - Frequently Asked Questions How have EYPT shares performed this year? Eyepoint Pharmaceuticals' stock was trading at $18.27 at the start of the year. Since then, EYPT shares have decreased by 98.7% and is now trading at $0.2330. How were Eyepoint Pharmaceuticals' earnings last quarter? Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.93) by $0.14. The firm earned $756 thousand during the quarter, compared to the consensus estimate of $231 thousand. Eyepoint Pharmaceuticals had a negative trailing twelve-month return on equity of 168.83% and a negative net margin of 13,281.23%. Read the conference call transcript. When did Eyepoint Pharmaceuticals' stock split? Shares of Eyepoint Pharmaceuticals reverse split on Wednesday, December 9th 2020.The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Eyepoint Pharmaceuticals' major shareholders? Eyepoint Pharmaceuticals' top institutional shareholders include Aberdeen Group plc (3.54%), State Street Corp (3.45%), Goldman Sachs Group Inc. (0.88%) and Algert Global LLC (0.51%). Insiders that own company stock include Jay S Duker, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine, David R Guyer and Ramiro Ribeiro. View institutional ownership trends. How do I buy shares of Eyepoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eyepoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyepoint Pharmaceuticals investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Alimera Sciences (ALIM), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Company Calendar Last Earnings11/12/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 EYPT's financial health is in the Red zone, according to TradeSmith. EYPT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:EYPT CIK1314102 Webwww.eyepoint.bio Phone(617) 926-5000Fax617-926-5050Employees214Year Founded1987Price Target and Rating Average Price Target for Eyepoint Pharmaceuticals$21.85 High Price Target$68.00 Low Price Target$0.50 Potential Upside/Downside+9,277.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$231.96 million Net Margins-13,281.23% Pretax Margin-13,275.96% Return on Equity-168.83% Return on Assets-130.92% Debt Debt-to-Equity RatioN/A Current Ratio3.30 Quick Ratio3.25 Sales & Book Value Annual Sales$31.37 million Price / Sales0.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book0.25Miscellaneous Outstanding Shares113,780,000Free Float81,789,000Market Cap$26.51 million OptionableOptionable Beta1.84 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:EYPT) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.